Tirzepatide is more cost-effective than semaglutide for knee osteoarthritis and obesity, optimizing resources for patients not seeking surgical options, which remain cost-effective for those eligible.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/are-semaglutide-and-tirzepatide-cost-effective-solutions-2025a1000od9?src=rss
Author :
Publish date : 2025-09-15 21:05:00
Copyright for syndicated content belongs to the linked Source.
